Journals / Turkish Journal of Medical Sciences / 2012 / Cilt: 42 - Sayı: 6

The levels of serum chemokines in patients with Behçet's disease

Pages
1105–1110
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, because chemokines insert their eff ects in the microenvironment and serum concentrations reflect a developing inflammatory process indirectly, we suggest that more comprehensive studies are needed to reveal the role of chemokines in the pathogenesis of the disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: As chemokines are involved in the regulation of immune responses and infl ammatory reactions, this study aimed to investigate the serum levels of some chemokines to determine whether they play roles in the pathogenesis of Behçet s disease (BD).
📊
Key Findings & Data:Materials and methods: The study comprised 64 cases, allocated to active or inactive patient groups.
💡
Conclusion & Impact:However, because chemokines insert their eff ects in the microenvironment and serum concentrations reflect a developing inflammatory process indirectly, we suggest that more comprehensive studies are needed to reveal the role of chemokines in the pathogenesis of the disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: As chemokines are involved in the regulation of immune responses and infl ammatory reactions, this study aimed to investigate the serum levels of some chemokines to determine whether they play roles in the pathogenesis of Behçet s disease (BD). Materials and methods: The study comprised 64 cases, allocated to active or inactive patient groups. The levels of serum macrophage inflammatory protein-1α (MIP-1α), epithelial neutrophil-activating protein-78 (ENA-78), and neutrophilactivating peptide-2 (NAP-2) were measured. Results: The serum levels of MIP-1α and ENA-78 were statistically higher in BD patients than controls (P = 0.032 and P = 0.023, respectively). However, NAP-2 levels did not differ significantly between patients and controls (P > 0.05). A significantly higher mean serum level of ENA-78 was found in patients with active disease compared to patients with inactive disease and controls (P = 0.029 and P = 0.003, respectively). However, mean serum MIP-1α and NAP-2 levels did not differ significantly between active and inactive patients (P > 0.05). Conclusion: In this study, there was a significant elevation of MIP-1α and ENA-78 supporting the role of neutrophil hyperactivity in BD. However, because chemokines insert their eff ects in the microenvironment and serum concentrations reflect a developing inflammatory process indirectly, we suggest that more comprehensive studies are needed to reveal the role of chemokines in the pathogenesis of the disease.

🔖

Cite This Article

İLHAN, N. F., ÇİÇEK, D., KÖKÇAM, İ., TURGUT, D. (2022). The levels of serum chemokines in patients with Behçet's disease. Turkish Journal of Medical Sciences, Cilt: 42 - Sayı: 6, 1105–1110. https://ajindex.com/articles/611146

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Kapsimali VD, Kanakis MA, Vaiopoulos GA, Kaklamanis PG. Etiopathogenesis of Beh çet’s disease with emphasis on the role of immunological aberrations. Clin Rheumatol 2010; 29: 1211- 6
  2. Tugal-Tutkun I. Behçet disease in the developing world. Int Ophthalmol Clin 2010; 50: 87-98
  3. Erkilic K, Evereklioglu C, Cekmen M, Ozkiris A, Duygulu F, Dogan H. Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Behçet’s disease: original contributions/clinical and laboratory investigations. Mediators Inflamm 2003; 12: 107-16
  4. Eksioglu-Demiralp E, Direskeneli H, Kibaroglu A, Yavuz S, Ergun T, Akoglu T. Neutrophil activation in Behçet’s disease. Clin Exp Rheumatol 2001; 19: 19-24
  5. Frassanito MA, Dammacco R, Cafforio P, Dammacco F. Th 1 polarization of the immune response in Behçet’s disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 1999; 42: 1967-74
  6. Dizdar O, Kalyoncu U, Karadag O, Akdogan A, Kiraz S, Ertenli I et al. Macrophage infl ammatory protein-1α: a link between innate immunity and familial Mediterranean fever? Cytokine 2007; 37: 92-5
  7. Salazar-Mather TP, Orange JS, Biron CA. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1α (MIP-1α)-dependent pathways. J Exp Med 1998; 187: 1-14
  8. Maurer M, von Stebut E. Macrophage inflammatory protein-1. Int J Biochem Cell Biol 2004; 36: 1882-6
  9. Walz A, Burgener R, Car B, Baggiolini M, Kunkel SL, Strieter RM. Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med 1991; 174: 1355-62
  10. Peveri P, Walz A, Dewald B, Baggiolini M. A novel neutrophilactivating factor produced by human mononuclear phagocytes. J Exp Med 1988; 167: 1547-59
  11. Moser B, Clark-Lewis I, Zwahlen R, Baggiolini M. Neutrophilactivating properties of the melanoma growth-stimulatory activity. J Exp Med 1990; 171: 1797-802
  12. Ozer HT, Erken E, Gunesacar R, Kara O. Serum RANTES, MIP-1α, and MCP-1 levels in Behçet’s disease. Rheumatol Int 2005; 25: 487-8
  13. International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet 1990; 335: 1078-80
  14. Saruhan-Direskeneli G, Yentür SP, Akman-Demir G, Işık N, Serdaroğlu P. Cytokines and chemokines in neuro-Behçet’s disease compared to multiple sclerosis and other